1st Department of Critical Care and Pulmonary Services, Evangelismos General Hospital, Athens, Greece.
1st Department of Critical Care and Pulmonary Services, Evangelismos General Hospital, Athens, Greece; and National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Respir Care. 2024 Oct 25;69(11):1361-1370. doi: 10.4187/respcare.11863.
Post-COVID-19 syndrome has affected millions of people, with rehabilitation being at the center of non-pharmacologic care. However, numerous published studies show conflicting results due to, among other factors, considerable variation in subject characteristics. Currently, the effects of age, sex, time of implementation, and prior disease severity on the outcomes of a supervised rehabilitation program after COVID-19 remain unknown.
This was a non-randomized case-control study. Subjects with post-COVID-19 sequelae were enrolled. Among study participants, those who could attend an 8-week, supervised rehabilitation program composed the intervention group, whereas those who couldn't the control group. Measurements were collected at baseline and 8 weeks thereafter.
Study groups ( = 119) had similar baseline measurements. Participation in rehabilitation ( = 47) was associated with clinically important improvements in the 6-min walk test (6MWT) distance, adjusted (for potential confounders) odds ratio (AOR) 4.56 (95% CI 1.95-10.66); 1-min sit-to-stand test, AOR 4.64 (1.88-11.48); Short Physical Performance Battery, AOR 7.93 (2.82-22.26); health-related quality of life (HRQOL) 5-level EuroQol-5D (Visual Analog Scale), AOR 3.12 (1.37-7.08); Montreal Cognitive Assessment, AOR 6.25 (2.16-18.04); International Physical Activity Questionnaire, AOR 3.63 (1.53-8.59); Fatigue Severity Scale, AOR 4.07 (1.51-10.98); Chalder Fatigue Scale (bimodal score), AOR 3.33 (1.45-7.67); Modified Medical Research Council dyspnea scale (mMRC), AOR 4.43 (1.83-10.74); Post-COVID-19 Functional Scale (PCFS), AOR 3.46 (1.51-7.95); and COPD Assessment Test, AOR 7.40 (2.92-18.75). Time from disease onset was marginally associated only with 6MWT distance, AOR 0.99 (0.99-1.00). Prior hospitalization was associated with clinically important improvements in the mMRC dyspnea scale, AOR 3.50 (1.06-11.51); and PCFS, AOR 3.42 (1.16-10.06). Age, sex, and ICU admission were not associated with the results of any of the aforementioned tests/grading scales.
In this non-randomized, case-control study, post-COVID-19 rehabilitation was associated with improvements in physical function, activity, HRQOL, respiratory symptoms, fatigue, and cognitive impairment. These associations were observed independently of timing of rehabilitation, age, sex, prior hospitalization, and ICU admission.
新冠病毒后遗症影响了数百万人,康复治疗成为非药物治疗的核心。然而,由于研究对象特征存在较大差异等诸多因素,大量已发表的研究结果相互矛盾。目前,年龄、性别、实施时间以及既往疾病严重程度对新冠病毒后监督康复计划的效果的影响尚不清楚。
这是一项非随机病例对照研究。纳入了患有新冠病毒后遗症的患者。在研究参与者中,能够参加 8 周监督康复计划的患者为干预组,而无法参加的患者为对照组。在基线和 8 周后收集测量数据。
研究组(n=119)基线测量值相似。参加康复治疗(n=47)与 6 分钟步行测试(6MWT)距离的临床显著改善相关,调整(潜在混杂因素)后比值比(AOR)为 4.56(95%置信区间 1.95-10.66);1 分钟坐站测试,AOR 4.64(1.88-11.48);短体适能测试,AOR 7.93(2.82-22.26);健康相关生活质量(HRQOL)5 级欧洲五维健康量表(视觉模拟评分),AOR 3.12(1.37-7.08);蒙特利尔认知评估,AOR 6.25(2.16-18.04);国际体力活动问卷,AOR 3.63(1.53-8.59);疲劳严重程度量表,AOR 4.07(1.51-10.98);查德尔疲劳量表(双峰评分),AOR 3.33(1.45-7.67);改良医学研究委员会呼吸困难量表(mMRC),AOR 4.43(1.83-10.74);新冠病毒后功能量表(PCFS),AOR 3.46(1.51-7.95);和慢性阻塞性肺疾病评估测试(COPD Assessment Test),AOR 7.40(2.92-18.75)。发病时间仅与 6MWT 距离呈边缘相关,AOR 0.99(0.99-1.00)。既往住院与 mMRC 呼吸困难量表的临床显著改善相关,AOR 3.50(1.06-11.51);和 PCFS,AOR 3.42(1.16-10.06)。年龄、性别和 ICU 入院与上述任何测试/评分量表的结果均无关联。
在这项非随机病例对照研究中,新冠病毒后康复治疗与身体功能、活动能力、HRQOL、呼吸症状、疲劳和认知障碍的改善有关。这些关联独立于康复治疗时间、年龄、性别、既往住院和 ICU 入院。